Clinical characteristics of patients used in figures 1 and 2
| No | Diagnosis | Sex M/F | Age (years) | Duration of disease (year)* | CDAI CAI | Endoscopic activity n/m/md/s1-151 | Biopsy location c/a/t/d/s/r1-152 | Mesalazine treatment yes/no | Involvement (ileal/ileocolonic/colonic/left-sided) diagnosis (DSC only) |
| 1–10 | CD | 4/6 | 19–54 | 1–17 | 187–412 | 0/2/4/4 | 5/1/0/3/1/0 | 7/3 | 0/8/2/NA |
| 11–24 | UC | 6/8 | 17–51 | 1–28 | 6–12 | 0/2/8/4 | 10/0/0/3/1/0 | 12/2 | NA/3/7/4 |
| 25 | DSC | F | 26 | 2 weeks | NA | md | s | No | Salmonellosis |
| 26 | DSC | M | 31 | 3 days | NA | md | s | No | Yersiniosis |
| 27 | DSC | F | 27 | 2 days | NA | s | s | No | Unclear inflammation adjacent to colonic carcinoma |
| 28 | DSC | F | 55 | 3 | NA | md | d | No | Diverticulitis |
| 29 | DSC | F | 61 | 7 | NA | md | d | No | Diverticulitis |
| 30 | DSC | M | 27 | 4 days | NA | md | s | No | Viral enterocolitis |
*Range (minimum–maximum).
↵1-151 n, none; m, mild; md, moderate; s, severe, according to endoscopist’s assessment of the biopsy site.
↵1-152 c, caecum; a, ascending colon; t, transverse colon; d, descending colon; s, sigmoid; r, rectum. Biopsy samples were always taken from the area showing the highest degree of inflammatory activity. Necrotic areas were not sampled.
NA, not applicable; CD, Crohn’s disease; UC, ulcerative colitis; DSC, disease specificity control; CDAI, Crohn’s disease activity index40; CAI, colitis activity index.41